Loading provider…
Loading provider…
Rheumatology Physician in Kansas City, KS
NPI: 1013036060Primary Practice Location
UNIVERSITY OF KANSAS HOSPITAL
4000 Cambridge St, Kansas City, KS
Primary Employer
Ku Internal Medicine
kansashealthsystem.com
HQ Phone
Get MD Ghaith's Phone Numberphone_androidMobile
Get MD Ghaith's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMO State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 136 | 173 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 95 | 127 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 52 | 52 |
| 4 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 13 | 19 |
| 5 | 99204New patient office or other outpatient visit, 45-59 minutes | 11 | 11 |
Authors: Jennifer King, Matthew Baker, Stamatina Danielides, Daniel Wallace, Anahita Deboo, Pantelis Pavlakis, Steven Carsons, R Scofield, Nancy Carteron
Journal: Arthritis Rheumatol
Publication Date: 2025-01-06
Authors: Samir Bhangle, Frederick Vivino
Journal: J Clin Rheumatol
Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial.
Authors: Tammy Utset, Daniel Wallace, Mark Genovese, Andreea Coca, Judith James, Alan Baer
Publication Date: 2018-07
Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators: Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc., Corbus Pharmaceuticals Inc.
Intervention / Treatment: DRUG: Placebo, DRUG: JBT-101
Lead Sponsor: Eli Lilly and Company
Collaborators: Incyte Corporation
Intervention / Treatment: DRUG: Placebo, DRUG: Baricitinib
Lead Sponsor: Eli Lilly and Company
Collaborators: Incyte Corporation
Intervention / Treatment: DRUG: Placebo, DRUG: Baricitinib